Palifermin reduces infection rate and hyperfibrinogenemia in patients treated with high-dose chemotherapy based on beam or BU-thiothepa.

about

Immune reconstitution post allogeneic transplant and the impact of immune recovery on the risk of infection.Italian consensus conference for the outpatient autologous stem cell transplantation management in multiple myeloma.

P2860

Q37509207-41E648B7-D79A-43BB-A39B-9DB74FEDA235 Q38797546-46CAC10A-85FF-412A-B769-F23EC5FD770A

P2860

Palifermin reduces infection rate and hyperfibrinogenemia in patients treated with high-dose chemotherapy based on beam or BU-thiothepa.

Item

http://www.wikidata.org/entity/Q40201079

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

2014年论文

@zh

2014年论文

@zh-cn

name

Palifermin reduces infection r ...... based on beam or BU-thiothepa.

@en

type

Item

label

Palifermin reduces infection r ...... based on beam or BU-thiothepa.

@en

prefLabel

Palifermin reduces infection r ...... based on beam or BU-thiothepa.

@en

P1476

Palifermin reduces infection r ...... based on beam or BU-thiothepa

@en

P2093

A Cupri

http://www.w3.org/2001/XMLSchema#string

A L Fauci

http://www.w3.org/2001/XMLSchema#string

D Berritta

http://www.w3.org/2001/XMLSchema#string

G Tripepi

http://www.w3.org/2001/XMLSchema#string

M Parisi

http://www.w3.org/2001/XMLSchema#string

P Spina

http://www.w3.org/2001/XMLSchema#string

S Leotta

http://www.w3.org/2001/XMLSchema#string

P2860

Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT

Palifermin for oral mucositis after intensive therapy for hematologic cancers

Prospective evaluation of oral mucositis in patients receiving myeloablative conditioning regimens and haemopoietic progenitor rescue.

Palifermin reduces incidence and severity of oral mucositis in allogeneic stem-cell transplant recipients.

In a high-dose melphalan setting, palifermin compared with placebo had no effect on oral mucositis or related patient's burden.

Keratinocyte growth factor is effective in the prevention of intestinal mucositis in patients with hematological malignancies treated with high-dose chemotherapy and autologous hematopoietic SCT: a video-capsule endoscopy study.

Infectious complication in 314 patients after high-dose therapy and autologous hematopoietic stem cell transplantation: risk factors analysis and outcome.

Impact of palifermin on intestinal mucositis of HSCT recipients after BEAM.

Comparision of benefits of early, delayed, and no administration of G-CSF after autologous peripheral blood stem cell transplantation in lymphoma patients.

P2888

bmt.2014.140

P304

1193-1197

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/BMT.2014.140

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Giuseppe Milone

P577

2014-07-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

263744861

http://www.w3.org/2001/XMLSchema#string

P6179

1021911700

http://www.w3.org/2001/XMLSchema#string

P698

25000456

http://www.w3.org/2001/XMLSchema#string

Palifermin reduces infection rate and hyperfibrinogenemia in patients treated with high-dose chemotherapy based on beam or BU-thiothepa.

about

P2860

P2860

Palifermin reduces infection rate and hyperfibrinogenemia in patients treated with high-dose chemotherapy based on beam or BU-thiothepa.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P407

P433

P478

P50

P577

P5875

P6179

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P407

P433

P478

P50

P577

P5875

P6179

P698